Stephen Simpson, CFA
Long only, growth at reasonable price, value, research analyst

Alkermes Still Not Getting Full Credit For Its Pipeline

Biotech is a strange world, one where investors often seem to prefer stories that are relatively weak on sales, earnings, and actual data. Maybe that makes a certain amount of sense - in the absence of data, investors are free to dream about blockbuster drugs and multi-baggers.

In the case of Alkermes (NASDAQ:ALKS), it would seem that having an actual cash flow-generating business is almost a detriment to the stock. Given that I believe Alkermes combines a strong (and fairly stable) royalty-generating business with a high-risk/high-reward, but undervalued, pipeline, I believe this is a stock worth considering even at these relatively elevated prices for biotech stocks.

A Stable Of Strong Horses

While Alkermes does boast over 20 commercial...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details